collection
MENU ▼
Read by QxMD icon Read
search

Urticaria

shared collection
41 papers 0 to 25 followers
https://www.readbyqxmd.com/read/28634900/review-of-physical-urticarias-and-testing-methods
#1
REVIEW
Mario Sánchez-Borges, Luis González-Aveledo, Fernan Caballero-Fonseca, Arnaldo Capriles-Hulett
PURPOSE OF REVIEW: This review aims to update the information available on the prevalence, clinical picture, diagnostic methods, and treatment of urticarias induced by external physical stimuli. RECENT FINDINGS: Physical urticarias are present in up to 5% of the general population, and in 10 to 50% of patients with chronic urticaria. Recent investigations have provided evidence that the presence of physical urticaria alone or when comorbid with chronic spontaneous urticaria is associated with a worse prognosis and duration...
August 2017: Current Allergy and Asthma Reports
https://www.readbyqxmd.com/read/28625805/responsiveness-and-minimal-important-difference-of-the-urticaria-control-test-uct
#2
Tatevik Ohanyan, Nicole Schoepke, Bediha Bolukbasi, Martin Metz, Tomasz Hawro, Torsten Zuberbier, Adriane Peveling-Oberhag, Petra Staubach, Marcus Maurer, Karsten Weller
This study demonstrates the responsiveness of the Urticaria Control Test (UCT). Changes of its score by 3 points or more reflect a clinically relevant change of disease control (minimal important difference).
June 15, 2017: Journal of Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/28566225/treatment-and-retreatment-with-omalizumab-in-chronic-spontaneous-urticaria-real-life-experience-with-twenty-five-patients
#3
Murat Türk, İnsu Yılmaz, Sakine Nazik Bahçecioğlu
BACKGROUND: Previous data have shown the high efficacy of omalizumab in chronic spontaneous urticaria (CSU). However, factors that may be effective on the response to therapy, relapse rates after drug discontinuation, and efficacy of retreatment remain unclear. This study aimed to determine the efficacy of omalizumab in CSU refractory to conventional therapy, to identify possible factors affecting treatment response and relapse, and also to evaluate the efficacy of retreatment on relapsed disease...
May 26, 2017: Allergology International: Official Journal of the Japanese Society of Allergology
https://www.readbyqxmd.com/read/28537934/alternative-treatments-for-chronic-spontaneous-urticaria-beyond-the-guideline-algorithm
#4
Gino A Vena, Marcus Maurer, Nicoletta Cassano, Torsten Zuberbier
PURPOSE OF REVIEW: The international EAACI/GALEN/EDF/WAO guideline suggests a stepwise approach for the therapeutic management of chronic spontaneous urticaria (CSU), outlined in an algorithm. The aim of this article is to summarize and review the evidence available on alternative treatment options for CSU outside of this algorithm. RECENT FINDINGS: Although CSU is a common disease, there are a limited number of high-quality studies, and only antihistamines and omalizumab are licensed for its treatment...
May 22, 2017: Current Opinion in Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/28513988/aquagenic-cutaneous-disorders
#5
REVIEW
Fang Wang, Yu-Kun Zhao, Ze-Yu Luo, Qian Gao, Wei Wu, Rashmi Sarkar, Di-Qing Luo
Aquagenic cutaneous disorders, which include aquagenic urticaria, aquagenic pruritus, and aquagenic acrokeratoderma, are a group of rare diseases characterized by skin lesions or discomfort induced by brief contact with water. Aquagenic urticaria is characterized by pruritic wheals that occur at the sites of water contact, either immediately or within minutes, and disappear within 30-60 min after water removal. Aquagenic pruritus presents with severe pruritus or a stinging, tingling, or burning sensation without any visible skin changes...
June 2017: Journal der Deutschen Dermatologischen Gesellschaft, Journal of the German Society of Dermatology: JDDG
https://www.readbyqxmd.com/read/28435464/clinical-efficacy-of-omalizumab-in-chronic-spontaneous-urticaria-is-associated-with-a-reduction-of-fc%C3%AE%C2%B5ri-positive-cells-in-the-skin
#6
Martin Metz, Petra Staubach, Andrea Bauer, Randolf Brehler, Janine Gericke, Michael Kangas, Joanna Ashton-Chess, Philip Jarvis, Panayiotis Georgiou, Janice Canvin, Rainer Hillenbrand, Veit J Erpenbeck, Marcus Maurer
Background. Treatment with omalizumab, a humanized recombinant monoclonal anti-IgE antibody, results in clinical efficacy in patients with Chronic Spontaneous Urticaria (CSU). The mechanism of action of omalizumab in CSU has not been elucidated in detail. Objectives. To determine the effects of omalizumab on levels of high affinity IgE receptor-positive (FcεRI(+)) and IgE-positive (IgE(+)) dermal cells and blood basophils. Treatment efficacy and safety were also assessed. Study design. In a double-blind study, CSU patients aged 18‑75 years were randomized to receive 300 mg omalizumab (n=20) or placebo (n=10) subcutaneously every 4 weeks for 12 weeks...
2017: Theranostics
https://www.readbyqxmd.com/read/28452145/how-to-manage-chronic-urticaria-beyond-guidelines-a-practical-algorithm
#7
Krzysztof Rutkowski, Clive E H Grattan
Chronic urticaria (CU) is a disease characterised by pruritic weals, angio-oedema or both occurring for at least 6 weeks. It encompasses spontaneous and inducible urticarias. The national and international guidelines outline the principles of treatment. Omalizumab, an anti-immunoglobulin E monoclonal antibody has transformed the management of many severe and treatment-refractory patients. However, current UK guidance on its use does not address the needs of those with less severe disease, inducible urticarias, idiopathic histaminergic angio-oedema without weals as a presentation of CU and omalizumab non-responders...
April 28, 2017: Clinical and Experimental Allergy: Journal of the British Society for Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/28407273/comorbidity-of-chronic-spontaneous-urticaria-and-autoimmune-thyroid-diseases-a-systematic-review
#8
REVIEW
P Kolkhir, M Metz, S Altrichter, M Maurer
Patients with chronic spontaneous urticaria (CSU) are widely held to often have other autoimmune disorders, including autoimmune thyroid disease. Here, we systematically evaluated the literature on the prevalence of thyroid autoimmunity in CSU and vice versa. There is a strong link between CSU and elevated levels of IgG antithyroid autoantibodies (AAbs), with most of a large number of studies reporting rates of ≥10%. Levels of IgG against thyroid peroxidase (TPO) are more often elevated in CSU than those of other IgG antithyroid AAbs (strong evidence)...
April 13, 2017: Allergy
https://www.readbyqxmd.com/read/28390587/clinical-features-of-adolescents-with-chronic-idiopathic-or-spontaneous-urticaria-review-of-omalizumab-clinical-trials
#9
Stanley Goldstein, Susan Gabriel, Farid Kianifard, Benjamin Ortiz, David P Skoner
BACKGROUND: Adults and adolescents were included in 3 phase 3 omalizumab trials in chronic idiopathic urticaria (CIU): ASTERIA I, ASTERIA II, and GLACIAL. OBJECTIVE: To describe the baseline clinical profile of adolescent patients with CIU enrolled in the omalizumab trials to add to the limited literature available on CIU in this population. METHODS: Data for patient demographics, baseline clinical disease characteristics, medical history, and previous CIU medication information (not efficacy assessments) from phase 3 omalizumab trials were pooled and descriptive statistical analyses performed for adolescent (12 to <18 years old) and adult (≥18 years old) subgroups...
April 2017: Annals of Allergy, Asthma & Immunology
https://www.readbyqxmd.com/read/28314658/management-of-chronic-inducible-urticaria-according-to-the-guidelines-a-prospective-controlled-study
#10
Emek Kocatürk, Pelin Kuteyla Can, Pırıl Etikan Akbas, Mehmet Copur, Ece Nur Degirmentepe, Kübra Kızıltac, Ralfi Singer
BACKGROUND: The recommended treatment approach in chronic inducible urticarias (CIndU) is the same as that for chronic spontaneous urticaria (CSU). But there is a lack of controlled trials assessing efficacy of available treatment options. OBJECTIVE: We aimed to evaluate the efficacy of treatment algorithm recommended by the guidelines and comparison of treatment responses in CIndU vs CSU. METHODS: This prospective parallel group controlled study included 70 CIndU and 66 CSU patients...
March 1, 2017: Journal of Dermatological Science
https://www.readbyqxmd.com/read/28293927/prevalence-and-risk-factors-of-urticaria-with-a-focus-on-chronic-urticaria-in-children
#11
Seung Jin Lee, Eun Kyo Ha, Hye Mi Jee, Kyung Suk Lee, Seung Won Lee, Mi Ae Kim, Dong Hyun Kim, Young Ho Jung, Youn Ho Sheen, Myong Soon Sung, Man Yong Han
PURPOSE: Limited data is available on the prevalence and risk factors of acute and chronic urticaria in children. Our purpose was to determine the prevalence and identify the risk factors of acute and chronic urticaria in Korean children. METHODS: This population-based study examined 4,076 children (age 4 to 13 years) who were enrolled in the 2015 prospective Seongnam Atopy Project (SAP 2015) in Korea. The parents completed an urticaria questionnaire that included questions regarding the duration, severity, and triggering factors of urticaria...
May 2017: Allergy, Asthma & Immunology Research
https://www.readbyqxmd.com/read/28299827/factors-linked-to-disease-severity-and-time-to-remission-in-patients-with-chronic-spontaneous-urticaria
#12
REVIEW
M Sánchez-Borges, F Caballero-Fonseca, A Capriles-Hulett, L González-Aveledo, M Maurer
Biomarkers useful for the evaluation and management of patients with chronic spontaneous urticaria (CSU) are not currently available. A review of various clinical and laboratory markers that have been studied to assess their value for determining the severity or predicting the evolution of disease in adult patients with CSU was carried out. A search of the medical literature on PubMed and MEDLINE including the terms urticaria, chronic urticaria, chronic idiopathic urticaria, CSU, severity, prognosis and treatment was performed...
March 16, 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/28226418/omalizumab-for-the-treatment-of-chronic-idiopathic-urticaria-systematic-review-of-the-literature
#13
REVIEW
Alessandro Tonacci, Lucia Billeci, Giovanni Pioggia, Michele Navarra, Sebastiano Gangemi
Omalizumab is recombinant humanized monoclonal antibody to immunoglobulin E. Guidelines for the treatment of chronic idiopathic urticaria (also known as chronic spontaneous urticaria) recommend the use of omalizumab as third-line therapy in addition to high doses of histamine receptor type 1 (H1 ) antihistamines when they are unsuccessful as first- and second-line therapy. We performed a systematic review of the literature to identify studies that evaluated the efficacy of omalizumab for the treatment of chronic idiopathic urticaria, in both controlled and real-world settings, to assess its potential role as a preferred therapy...
April 2017: Pharmacotherapy
https://www.readbyqxmd.com/read/22978406/how-not-to-miss-autoinflammatory-diseases-masquerading-as-urticaria
#14
REVIEW
K Krause, C E Grattan, C Bindslev-Jensen, M Gattorno, T Kallinich, H D de Koning, H J Lachmann, D Lipsker, A A Navarini, A Simon, C Traidl-Hoffmann, M Maurer
Urticarial skin reactions are one of the most frequent problems seen by allergists and clinical immunologists in daily practice. The most common reason for recurrent wheals is spontaneous urticaria. There are, however, several less common diseases that present with urticarial rash, such as urticarial vasculitis and autoinflammatory disorders. The latter include cryopyrin-associated periodic syndrome and Schnitzler's syndrome, both rare and disabling conditions mediated by increased interleukin-1 secretion. Apart from the urticarial rash, patients are suffering from a variety of systemic symptoms including recurrent fever attacks, arthralgia or arthritis and fatigue...
December 2012: Allergy
https://www.readbyqxmd.com/read/28160338/h1-antihistamine-refractory-chronic-spontaneous-urticaria-it-s-worse-than-we-thought-first-results-of-the-multicenter-real-life-aware-study
#15
M Maurer, P Staubach, U Raap, G Richter-Huhn, A Bauer, F Ruëff, T Jakob, A S Yazdi, V Mahler, N Wagner, U Lippert, U Hillen, A Schwinn, M Pawlak, N Behnke, K Chaouche, N Chapman-Rothe
BACKGROUND: Most data on chronic spontaneous urticaria (CSU) originate from highly selected patient populations treated at specialized centres. Little is known about CSU patient characteristics and the burden of CSU in routine clinical practice. AWARE (A World-wide Antihistamine-Refractory chronic urticaria patient Evaluation) is an ongoing global study designed to assess chronic urticaria in the real-life setting. OBJECTIVE: To describe the baseline characteristics of the first 1539 German AWARE patients with H1-antihistamine-refractory CSU...
May 2017: Clinical and Experimental Allergy: Journal of the British Society for Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/28094108/analysis-of-primary-treatment-and-prognosis-of-spontaneous-urticaria
#16
Toshihiko Tanaka, Makiko Hiragun, Michihiro Hide, Takaaki Hiragun
BACKGROUND: The prognosis of spontaneous urticaria in association with early treatment remains unclear. In this study, we retrospectively studied the prognosis of acute spontaneous urticaria in relation to age and treatments in a local clinic of dermatology. METHODS: Out of 5000 patients who visited an office dermatology clinic, clinical records of patients with spontaneous urticaria were extracted. Their prognosis and the relation to age and treatments were analyzed by the Kaplan-Meier method and generalized Wilcoxon test...
January 13, 2017: Allergology International: Official Journal of the Japanese Society of Allergology
https://www.readbyqxmd.com/read/28098370/effectiveness-of-phototherapy-in-chronic-urticaria
#17
S F Thomsen
No abstract text is available yet for this article.
January 2017: British Journal of Dermatology
https://www.readbyqxmd.com/read/28125304/omalizumab-for-treating-chronic-spontaneous-urticaria-an-expert-review-on-efficacy-and-safety
#18
Ana M Giménez-Arnau
Chronic spontaneous urticaria (CSU) is characterized by the recurrence of itchy hives and/or angioedema for greater than six weeks, with no known external trigger. Omalizumab, a humanized, recombinant, monoclonal anti-IgE antibody, is the only approved add-on therapy for H1-antihistamine refractory CSU patients. Areas covered: The objective of this article is to discuss the mechanism of action, pharmacokinetics and pharmacodynamics of omalizumab for the treatment of CSU. The review also summarizes efficacy and safety data from proof-of-concept, Phase II (X-QUISITE, MYSTIQUE), and pivotal Phase III omalizumab studies (ASTERIA I, ASTERIA II, and GLACIAL)...
January 26, 2017: Expert Opinion on Biological Therapy
https://www.readbyqxmd.com/read/28094120/omalizumab-associated-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss-syndrome
#19
Salik Nazir, Niranjan Tachamo, Shoaib Bilal Fareedy, Muhammad Sohail Khan, Saroj Lohani
No abstract text is available yet for this article.
March 2017: Annals of Allergy, Asthma & Immunology
https://www.readbyqxmd.com/read/28111112/intrauterine-uterine-contraception-and-chronic-urticaria-a-case-series
#20
Javen Wunschel, Jill A Poole
No abstract text is available yet for this article.
March 2017: Annals of Allergy, Asthma & Immunology
label_collection
label_collection
7989
1
2
2017-02-02 05:35:31
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"